INmune Bio Inc. (NASDAQ: INMB) announced results from MRI imaging analyses of its Phase 2 MINDFuL clinical trial testing XPro1595 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE